Compare FWRD & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | EVO |
|---|---|---|
| Founded | 1981 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 568.6M |
| IPO Year | 2024 | 2007 |
| Metric | FWRD | EVO |
|---|---|---|
| Price | $17.10 | $1.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $26.00 | $4.56 |
| AVG Volume (30 Days) | ★ 370.4K | 71.6K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | N/A |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $1.47 | $18.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.86 | $1.33 |
| 52 Week High | $31.18 | $3.87 |
| Indicator | FWRD | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 56.55 |
| Support Level | $14.72 | $1.50 |
| Resistance Level | $18.36 | $1.97 |
| Average True Range (ATR) | 1.34 | 0.06 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 49.89 | 59.38 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.